Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Bimatoprost Gel on Eyelash Growth

This study has been completed.
Information provided by (Responsible Party):
Duke University Identifier:
First received: September 10, 2010
Last updated: July 14, 2014
Last verified: September 2010
A internally controlled, single-blinded, randomized controlled trial to investigate the use of Bimatoprost eyelash gel on eyelash growth and appearance in breast cancer patients who suffer from madarosis (loss of eyelashes) due to the side effects of chemotherapy. IND and IRB approval have been obtained.

Condition Intervention Phase
Drug: Bimatoprost eyelash gel
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Role of Bimatoprost Eyelash Gel in Chemotherapy-induced Madarosis: an Analysis of Efficacy and Safety

Resource links provided by NLM:

Further study details as provided by Duke University:

Primary Outcome Measures:
  • eyelash length [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    eyelash ruler used to measure eyelash length

Secondary Outcome Measures:
  • eyelash pigment [ Time Frame: 6 mos ] [ Designated as safety issue: No ]
    blinded grader used digital photos to grade degree of pigment on scale of 1-5

  • eyelash thickness [ Time Frame: 6 mos ] [ Designated as safety issue: No ]
    blinded grader used digital photos to grade degree of thickness on scale of 1-5

  • eyelash amount [ Time Frame: 6 mos ] [ Designated as safety issue: No ]
    blinded grader used digital photos to grade degree of amount by counting lashes

  • eyelash side effects [ Time Frame: 6 mos ] [ Designated as safety issue: Yes ]
    any side effects (irritation, allergy, iop change, visual acuity, macular edema, uveitis, iris color change, etc... were assessed

Enrollment: 20
Study Start Date: February 2007
Study Completion Date: December 2008
Primary Completion Date: September 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Bimatoprost treated eyelid
one eyelid of the patient was randomized to the treatment arm and given the gel to use
Drug: Bimatoprost eyelash gel
Bimatoprost 0.03% solution was compounded into a gel - patients used on eyelash margin once daily placing gel with a fingertip or Q-tip for 6 months
Other Name: lumigan
No Intervention: control arm - no gel
the other fellow eyelid of the patient did not receive any treatment until month 4 and the patient crossed over to treating both eyelids


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18-80 YO females
  • madarosis or hypotrichosis (loss of eyelashes) due to chemotherapy used to treat breast cancer
  • only breast cancer patients

Exclusion Criteria:

  • inability to follow up, apply gel
  • active eye/eyelid infection or inflammatory process
  • cancer not related to breast cancer, healthy patients
  • males
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01200251

United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Duke University
  More Information

Responsible Party: Duke University Identifier: NCT01200251     History of Changes
Other Study ID Numbers: 9459  71320 
Study First Received: September 10, 2010
Last Updated: July 14, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Hair Diseases
Skin Diseases
Antihypertensive Agents processed this record on December 02, 2016